Navigating the valley of death: a how-to from an investor’s perspective

Core Insights - The biotech industry is highly competitive, particularly in the area of advanced therapeutic medicinal products (ATMPs), requiring companies to distinguish themselves to attract investor capital [1] - Despite challenges, investor engagement remains strong, with a reported 70.9% increase in total venture financing deal value from Q2 to Q3 2025 [2] - A survey indicates that 39% of industry respondents are optimistic about biotech funding recovery in the next year, a 24% increase from May 2025 [3] Investment Considerations - Investors prioritize companies with solid data addressing unmet medical needs, emphasizing the importance of data in reducing risk and enhancing company value [5] - A robust data package and a strong intellectual property (IP) strategy are critical factors for attracting investment [6] - Companies should strategically position themselves based on their data package and differentiate from competitors and previous failures in the market [7] - Identifying the latest developments in the industry and using relevant positive controls can help investors understand how a new drug compares to existing standards of care [8]